95 related articles for article (PubMed ID: 11326658)
41. [Detection of serum S100 protein and tissue polypeptide-specific antigen for diagnosis and treatment of breast cancer].
Luo RC; He XB; Cai HB; Li AM
Di Yi Jun Yi Da Xue Xue Bao; 2004 Jan; 24(1):102-4. PubMed ID: 14724113
[TBL] [Abstract][Full Text] [Related]
42. Differential percentage of serum prostate-specific antigen subforms suggests a new way to improve prostate cancer diagnosis.
Sarrats A; Comet J; Tabarés G; Ramírez M; Aleixandre RN; de Llorens R; Peracaula R
Prostate; 2010 Jan; 70(1):1-9. PubMed ID: 19670261
[TBL] [Abstract][Full Text] [Related]
43. Notable relationship between the level of tumor marker TPS in serum and survival in breast cancer.
Bremer K; Eklund G; Björklund B
Anticancer Res; 1996; 16(2):905-9. PubMed ID: 8687149
[TBL] [Abstract][Full Text] [Related]
44. Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters.
Suzuki H; Akakura K; Igarashi T; Ueda T; Ito H; Watanabe M; Nomura F; Ochiai T; Shimada H
J Urol; 2004 Jan; 171(1):182-6. PubMed ID: 14665872
[TBL] [Abstract][Full Text] [Related]
45. Serum levels of cytokeratin-18 (tissue polypeptide-specific antigen) in liver diseases.
Gonzalez-Quintela A; Mallo N; Mella C; Campos J; Perez LF; Lopez-Rodriguez R; Tome S; Otero E
Liver Int; 2006 Dec; 26(10):1217-24. PubMed ID: 17105587
[TBL] [Abstract][Full Text] [Related]
46. Early predicting recurrent cervical cancer with combination of tissue polypeptide specific antigen (TPS) and squamous cell carcinoma antigen (SCC).
Hung YC; Shiau YC; Chang WC; Kao CH; Lin CC
Neoplasma; 2002; 49(6):415-7. PubMed ID: 12584591
[TBL] [Abstract][Full Text] [Related]
47. Production of serum-free and total prostate-specific antigen due to prostatic intraepithelial neoplasia.
Minardi D; Galosi AB; Dell'Atti L; Hanitzsch H; Mario P; Muzzonigro G
Scand J Urol Nephrol; 2002; 36(5):323-9. PubMed ID: 12487735
[TBL] [Abstract][Full Text] [Related]
48. Procollagen type 1 amino-terminal propeptide: a marker for bone metastases in prostate carcinoma.
Klepzig M; Jonas D; Oremek GM
Anticancer Res; 2009 Feb; 29(2):671-3. PubMed ID: 19331219
[TBL] [Abstract][Full Text] [Related]
49. Tissue polypeptide specific antigen (TPS) as a tumor marker in renal cell carcinoma.
Chang CH; Wu HC; Yen RF; Kao A; Lin CC; Lee CC
Anticancer Res; 2002; 22(5):2949-50. PubMed ID: 12530023
[TBL] [Abstract][Full Text] [Related]
50. Elevated serum progastrin-releasing peptide (31-98) in metastatic and androgen-independent prostate cancer patients.
Yashi M; Muraishi O; Kobayashi Y; Tokue A; Nanjo H
Prostate; 2002 May; 51(2):84-97. PubMed ID: 11948963
[TBL] [Abstract][Full Text] [Related]
51. [Relation between the serum tissue polypeptide specific antigen level and the biological demeanour of lung cancer].
Chen M; Liu J; Yu W; Lu B; Dai Y
Zhonghua Jie He He Hu Xi Za Zhi; 2002 May; 25(5):262-4. PubMed ID: 12133315
[TBL] [Abstract][Full Text] [Related]
52. Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort.
Tahir SA; Frolov A; Hayes TG; Mims MP; Miles BJ; Lerner SP; Wheeler TM; Ayala G; Thompson TC; Kadmon D
Clin Cancer Res; 2006 Aug; 12(16):4872-5. PubMed ID: 16914574
[TBL] [Abstract][Full Text] [Related]
53. [Combined assay of serum prostate specific antigen and chromogranin A helps diagnosis of prostate cancer].
Sun CC; Zheng W; Kong CZ; Wang X; Yang CM
Zhonghua Nan Ke Xue; 2006 Oct; 12(10):904-5, 909. PubMed ID: 17121020
[TBL] [Abstract][Full Text] [Related]
54. [Vascular endothelial growth factor and insulin-like-growth factors in prostate cancer. ].
Trapeznikova MF; Shibaeva AN; Ianshin AA; Urenkov SB; Mironova OS; Kazantseva IA; Kushlinskiĭ NE
Urologiia; 2004; (1):17-21. PubMed ID: 15022438
[TBL] [Abstract][Full Text] [Related]
55. Significance of the evaluation of the tissue proliferation specific marker (TPS) and the carcinoembryonal antigen (CEA) in patients with ulcerative colitis and adenocarcinoma.
Krauss H; Ignyś I; Kopczyński Z; Piatek J
Med Sci Monit; 2002 Jan; 8(1):CR48-51. PubMed ID: 11791131
[TBL] [Abstract][Full Text] [Related]
56. Role of tissue polypeptide specific antigen in the detection of prostate cancer.
Onur R; Orhan I; Ilhan N; Semercioz A
Urol Int; 2002; 69(4):278-82. PubMed ID: 12444283
[TBL] [Abstract][Full Text] [Related]
57. Circulating prolactin and TPS in monitoring the clinical course of male patients with metastatic tongue cancer: a preliminary study.
Bhatavdekar JM; Patel DD; Vora HH; Balar DB
Anticancer Res; 1993; 13(1):237-40. PubMed ID: 7682801
[TBL] [Abstract][Full Text] [Related]
58. Serum osteoprotegerin levels are increased in patients with advanced prostate cancer.
Brown JM; Vessella RL; Kostenuik PJ; Dunstan CR; Lange PH; Corey E
Clin Cancer Res; 2001 Oct; 7(10):2977-83. PubMed ID: 11595685
[TBL] [Abstract][Full Text] [Related]
59. Tissue polypeptide specific antigen (TPS) and carbohydrate antigen 125 (CA-125) in the early prediction of recurrent ovarian cancer.
Yeh LS; Hung YC; Kao A; Lin CC; Lee CC
Anticancer Res; 2002; 22(6B):3669-71. PubMed ID: 12552974
[TBL] [Abstract][Full Text] [Related]
60. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer.
Noguchi M; Noda S
J Urol; 2001 Sep; 166(3):1106-10. PubMed ID: 11490307
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
